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The combination of cytotoxic therapies and antiangiogenic agents is emerging as a most promising strategy in the treatment of
malignant tumors. However, the timing and sequencing of these treatments seem to play essential roles in achieving a synergic
outcome. Using a mathematical modeling approach that is grounded on available experimental data, we investigate the spatial and
temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Our model suggests that the experimental
success of the nanoscale delivery system depends crucially on the trapping of chemotherapeutic agents within the tumor tissue.
The numerical results also indicate that substantial further improvements in the eﬃciency of the nanoscale delivery system can be
achieved through an adjustment of the temporal targeting mechanism.
1. Introduction
The growth of a tumor beyond an avascular state requires the
expansion of its vascular network, a process which is realized
through the recruitment of host vasculature (angiogenesis)
and/or vasculogenesis. Although the inhibition of tumor
angiogenesis represents a promising approach to the treat-
ment and control of cancers, recent preclinical studies have
suggested that currently available antiangiogenic strategies
are unlikely to produce significant therapeutic gains on
their own but rather will need to be used in combination
with conventional treatments to achieve maximal benefit
[1, 2]. To date, however, experimental studies combining
antiangiogenic and cytotoxic therapies have shown mixed
results [3–9], perhaps in part due to diﬀerences in scheduling
and sequencing of these modalities.
Currently, one major challenge to the successful com-
bination of conventional and antiangiogenic therapies is
that the administration of an antiangiogenic agent impairs
blood flow inside the tumor microenvironment, thus pre-
venting eﬃcient delivery of the chemotherapeutic agent.
This diﬃculty must also be reconciled with the emerging
notion of “normalization” of tumor vasculature. The tumor
vascular network that arises from abnormal angiogenesis
is spatially and temporally heterogeneous with defective
endothelium, basement membrane, and pericyte coverage
and is characterized by interstitial hypertension, hypoxia,
and acidosis [2]. Although high global blood flow is a feature
of many tumors, the irregular tumor vasculature is very
ineﬃcient at delivering nutrients, as well as chemotherapeu-
tic drugs, to malignant cells. It has been suggested [1, 2]
that the judicious administration of certain antiangiogenic
agents can structurally and functionally “normalize” the
abnormal tumor vascular network, rendering the vasculature
more conducive to the eﬃcient delivery of both drugs
and nutrients to the targeted cancer cells. This transient
normalization is characterized by more regular vascular
morphology and basement membrane structure, increased
pericyte coverage, and decreased hypoxia and interstitial
fluid pressure. Recent experimental and clinical studies have
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Figure 1: Confocal micrographs of tissue cross sections harvested
from tumor-bearing mice at 24 h after injection with imaging-
nanocells. Mice were injected with nanocells labeled with semicon-
ductor nanocrystals (quantum dots) to monitor the distribution
and leakage from the vessels in the tumor and normal tissues. The
sections were immunostained for von Willebrand Factor (vWF) to
delineate vasculature. Images were captured using a Zeiss LSM510
confocal microscope at 512 × 512 pixel resolution. The sections
were excited with a 488 nm laser, and emission was absorbed at
FITC (vWF) and Rhodamine (QD) wavelengths. The nanocells
were found to be spatially restricted within normal vasculature as
seen in the overlap (yellow) of the red and green signal in the merge
images but extravasate out from the tumor vasculature at 24 h as
seen by the predominantly red signal (merge).
shown that blockade of VEGF (vascular endothelial growth
factor) signaling, passively prunes some of the immature and
leaky vessels of tumors, and actively remodels the remaining
vasculature, resulting in a more normalized network [10–
12]. Even more recently, it has been shown that creation
of perivascular nitric oxide gradients may also result in the
normalization of tumor vasculature [13].
A severe limitation to taking advantage of a normalized
vascular network is that such a state lasts for only a short
period of time [12, 14–16]. After the transient window of
vascular normalization has passed, both tumor oxygenation
and penetration of chemotherapeutic drugs decrease. The
ensuing hypoxia activates hypoxia-inducible factor (HIF-
1α, upregulating many genes involved in angiogenesis, and
renders tumor cells resistant to chemotherapeutic agents
[17, 18]. Thus, spatial and temporal tumor targeting plays
a critical role in devising eﬃcient combination therapeutic
strategies.
Sengupta et al. [19] recently designed a novel delivery sys-
tem (termed a nanocell) comprising a nanoscale pegylated-
lipid envelope coating a nuclear nanoparticle. A chemothera-
peutic agent (doxorubicin) is conjugated to the nanoparticle
and an antiangiogenic agent (combretastatin) is trapped
within the lipid envelope. The nanocells extravasate into
the tumor through the enhanced permeation and retention
(EPR) eﬀect [20, 21] (see Figure 1), a consequence of the
highly leaky nature of tumor vasculature (having pores with
diameters of 400–600 nm). This is clearly visible in Figure 1
by the preferential accumulation of nanocells (labeled with
quantum dots) in the tumor compared to other vascularised
tissues: the nanocells are spatially restricted within normal
vasculature but extravasate out from the tumor vasculature
[19]. The rapid release of the antiangiogenic agent results
in at least a partial collapse of the network of tumor blood
vessels. The entrapped nanoparticles then slowly release
the chemotherapeutic drugs, which remain localized due to
the disruption of the nearby vasculature. Sengupta et al.
[19] compared the eﬀects of sequential drug delivery using
nanocells with several conventional approaches on mice with
B16 : F10 melanomas or Lewis lung carcinomas. Animals
treated with nanocells containing both drugs showed a better
tumor response than any of the other treatment groups.
While the nanoscale delivery approach outlined above
produced a markedly improved eﬀect on tumor control,
there remains potential for further refinement of the release
kinetics. This motivated us to adapt a mathematical model
[22], which incorporates tumor cells, vascular network, as
well as their interplay, and the eﬀects of chemotherapy and
antiangiogenic therapy to the experimental system studied
by Sengupta et al. The details of this model are described
in Sections 2 and 3 which discuss the mechanism for the
synergistic eﬀect of the nanocell treatment suggested by our
model, and how it may be possible to improve the eﬃciency
of the nanocell treatment even further.
2. Methods
In order to devise an eﬃcient combination of cytotoxic
and antiangiogenic therapies, it is essential to take into
consideration the mechanism and timing of tumor vessel
response to antiangiogenic agents, as well as the coupling
between tumor growth, the vascular network, and response
to cytotoxic agents. We have recently developed a mathe-
matical model that incorporates tumor cells and the vascular
network, as well as their interactions, and applied it to study
the combination of antiangiogenic and radiotherapeutic
treatments [22]. The experimental data of Winkler et al. [12]
were used to estimate the model parameters and validate
its predictions. The results indicated that application of
antiangiogenic therapy, which temporarily results in better
delivery of therapeutic agents, in advance of radiotherapy, is
themost eﬀective approach, consistent with the experimental
results.
In this paper, we build upon a previous mathematical
model [22] by including the eﬀects of chemotherapy and the
sequential release kinetics of nanocells. In formulating the
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model our guiding principle is tomakeminimal assumptions
about the underlying phenomenology of cellular processes
while incorporating the essential features of the experiments
by Sengupta et al. [19]. A key feature of the latter is the
release kinetics of the drugs in nanocells: combretastatin
has a rapid release (reaching significant levels within 12 h),
while doxorubicin releases more slowly extending over 15
days (compared to approximately 4 days for liposomes). Our
mathematical model incorporates this temporal targeting
profile and allows complete control over other possible
factors contributing to the increased eﬀectiveness of the
nanocell treatment, such as diﬀerences in the total amount of
drugs delivered to the cancer cells. Thus, we can directly test
and further investigate the temporal targeting mechanism
proposed by Sengupta et al. [19].
2.1. Tumor Cells and Vascular Network. Following previous
studies of tumor growth, we model the density of cancer
cells (at position x at time t) by a spatiotemporal field
n(x, t) according to a variant of the Fisher equation (below).
The novel aspect of our approach is to similarly introduce
a field m(x, t) to model the density of blood vessels. This
circumvents accounting for the precise nature of blood flow
and, as demonstrated earlier [22], the key features of the
interplay between growth and blood supply can be captured
by the evolution equations:
∂n
∂t
= ∇2n + n(1− n) + α˜1m(x, t)n, (1)
∂m
∂t
= ˜D2∇2m +m
[
α˜ + ˜βm + γ˜m2
]
+ α˜2n(x, t)m. (2)
For simplicity, the above equations are presented in dimen-
sionless form. They are related to the corresponding dimen-
sionful equations via the transformations t → ρt, x →
√
ρ/D1x, and n → n/nlim [22], where ρ is the net proliferation
rate, D1 is the diﬀusion coeﬃcient of tumor cells, and nlim is
the “carrying capacity” for tumor cells.
For α˜1 = 0, (1) is the (dimensionless) Fisher equation,
which has two fixed points: an unstable fixed point at n∗ = 0
(no population at all) and a stable fixed point at n∗ = 1
(where the population saturates to the carrying capacity).
In the absence of the nonlinear term, that is, for the simple
exponential form and α˜1 = 0, integrating both sides of
(1) leads, for a constant diﬀusion coeﬃcient, to a simple
exponential increase in the number of cells. The growth
of a tumor beyond an avascular state (up to a maximum
size of about 1-2mm in diameter) requires the development
of a vascular network. The additional term α˜1mn in (1)
indicates that tumor growth is enhanced by the presence
of vasculature. Mathematically, this results in a stable fixed
point at n∗ = 1 + α˜1m∗; see the following.
Following Kohandel et al. [22] (equations (6) and (8) of
Kohandel et al. [22] contain typos in the interaction terms
α1K(x, t)c and α˜1K(x, t)c which, in the notation of Kohandel
et al. [22], should in fact read α1m(x, t)c and α˜1m(x, t)c,
resp.), we use (2) to take into account the heterogeneous
tumor vasculature. This coarse-grained model, instead of the
exact pattern of vessels, produces islands of vascular and
nonvascular networks. For α˜2 = 0, and setting α˜ = −1,
˜β = 3, and γ˜ = −2, we obtain two stable fixed points for
m∗ at 0 and 1 and an unstable one at 1/2. Starting from
a random (positively distributed and close to zero) initial
configuration form(x, 0), (2) produces randomly distributed
islands of m = 1 (vascular) and m = 0 (non vascular). The
last term in (2), α˜2nm, represents the eﬀect of tumor cells
on the development of vessels. We assume that the tumor
cells produce the proangiogenic cytokines, leading to the
extension of the vascular network; in our phenomenological
approach, we assume that the higher density of cancer cells
creates higher vascular density. In fact, a nonzero α˜2 shifts
the stable fixed points to
m∗ = 1
4
(
3 + α˜1α˜2 ±
√
8(α˜2 − 1) + (3 + α˜1α˜2)2
)
. (3)
For example, for α˜1 = 1.1 and α˜2 = 0.9 (obtained
from fits to experimental data, see the results and discussion
section), m∗ = 0.02, 1.97. Thus the fixed point at 1 moves
to a higher value, indicating that the tumor vascular density
is higher than in the corresponding normal tissue. This
increased value will also be utilized in modeling of the poor
delivery characteristics of the tumor vasculature, as well as
the eﬀect of antiangiogenic therapy; see below.
2.2. Delivery of Nanocells and Liposomes. Following the same
strategy as above, we model the spatiotemporal variations of
liposomes and nanocells by concentration fields Ci(x, t), the
discrete index i labeling the drug administration at time ti.
The permeation of nanoparticles within a tumor depends on
their sizes; large nanoparticles of the order of 100 nm (which
is the case in Sengupta et al. 2007 experiments) appear to stay
close to the vasculature [23]. Hence, we assume that diﬀusion
of liposomes and nanocells within the tissue surrounding
the tumor, as well as reabsorption of these particles into the
blood vessels, can be neglected. The evolution of the field
Ci(x, t) is then modeled by the dimensionless equation,
∂Ci
∂t
= ˜δΓi(t)m(x, t) exp
[
−
(
m(x, t)
mlim
)2
]
. (4)
The function Γi(t) represents the (average) concentration
of the liposomes and nanocells in the blood vessels (see
Section 2.4). The tumor vasculature is structurally and
functionally abnormal, and the vessels are very ineﬃcient
at delivering nutrients and chemotherapeutic drugs. This
poor delivery could be due to defective vascular structure,
lack of perfusion of tumor blood vessels, inconsistent flow,
and elevated interstitial fluid pressure [24]. However, there is
growing evidence that vascular eﬃciency can be improved
with antiangiogenic therapy through the “normalization”
process [1, 2]. In (4), the poor delivery of tumor vessels is
modeled by the function m exp[−(m/mlim)2]. For mlim =√
2, this function has a maximum at m = 1, corresponding
to the eﬃcient delivery of normal vessels. For m > 1,
which corresponds to tumor vasculature (e.g., α˜1 = 1.1
and α˜2 = 0.9 gives m∗ = 1.97, as mentioned in the
previous section), the delivery decreases. Finally, m < 1
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corresponds to immature or degraded vessels, resulting again
in ineﬃcient nutrient or drug delivery. Hence, for a tumor
vasculature, decreasing the field m to values close to one,
by the administration of an antiangiogenic agent, results in
improved vascular eﬃciency and better delivery of nutrients
and chemotherapeutic agents [22]. The exponential term
therefore accounts for the poor delivery of vasculature as well
as the increase in the delivery of liposomes and nanocells
to tumor cells through normalization. One should note that
strong dosage of the antiangiogenic drug may lead to values
of m less than one, leading to either poor delivery through
immature vessels or complete regression of the vasculature
[24].
2.3. Drug Release from Nanocells and Liposomes. Next, we
denote by c(x, t) and d(x, t) the concentrations of free
antiangiogenic and chemotherapeutic agents released from
liposomes and nanocells into the tumor tissue, respectively.
The temporal and spatial evolution of these fields is modeled
by the dimensionless equations
∂c
∂t
= ˜D3∇2c + ˜λ(C)R(C)j (x, t)− ν˜(C)c, (5)
∂d
∂t
= ˜D4∇2d + ˜λ(D)R(D)j (x, t)− μ˜m(x, t)d − ν˜(D)d. (6)
We shall contrast the four types of treatment tested in the
experiments via the index j = 1–4, denoting chemotherapy
(NC[D], j = 1), antiangiogenic therapy (L[C], j = 2),
simple liposome encapsulating both (L[CD], j = 3), and
nanocells (NC[CD], j = 4). Free antiangiogenesis and
chemotherapy agents released from nanocells and liposomes
are small enough to diﬀuse through the tumor tissue (first
terms in the right side of (5) and (6); ˜D3 and ˜D4 are
dimensionless diﬀusion coeﬃcients). The term −μ˜m(x, t)d
describes the reabsorption of free chemotherapy drugs into
the blood vessels. We assume that no such term is present
in the equation for c(x, t) since antiangiogenic drugs act
on normal as well as on abnormal blood vessels, which
prevents absorption. However, both equations involve terms
of the form −ν˜(C)c and −ν˜(D)d, which describe the natural
decay of free drugs. The release of free chemotherapy and
antiangiogenesis agents in (5) and (6), that is, ˜λ(C,D)R(C,D)j ,
proceeds according to
R(C,D)j (x, t) =
∑
i
RP(C,D)i, j (t)Ci(x, t), (7)
in which the sum runs over all administration times ti. The
release profiles RP(C,D)i, j (t) are either identical to zero or satisfy
∑
i
∫ t f
0
RP(C,D)i, j (t)dt = 1, (8)
where, as above, the sum runs over all administration times
and t f = 17 days is the longest time considered in the
experiments by Sengupta et al. [19]. The above condition
on the release profiles fixes the total amount of drugs
released from liposomes and nanocells over the time interval
considered in the experiments by Sengupta et al. [19] and,
thus, ensures a fair comparison of diﬀerent therapeutic
strategies in our model.
Finally, the eﬀects of chemotherapy and antiangiogenic
therapy on cancer cells and blood vessels are modeled by
∂n(x, t)
∂t
∣
∣
∣
∣
chemo
= − ˜A(D)d(x, t)n, for j = 1, 3, 4,
∂m(x, t)
∂t
∣
∣
∣
∣
anti
= − ˜A(C)c(x, t)m, for j = 2, 3, 4,
(9)
where the vertical lines indicate that the above terms are
added to (1) and (2), respectively. Here, ˜A(D) and ˜A(C)
represent the strength of chemotherapy and antiangiogenic
therapy, respectively; d(x, t) and c(x, t) are defined by (5) and
(6). The details of the above model and its parameterization
are discussed in the following.
2.4. Release Profiles. To determine the release profiles,
RP(C,D)i, j (t) for j = 1–4, we first note that NC[D] only
involves chemotherapy (but does not contain antiangiogenic
therapy); thus, RP(C)i,1 (t) = 0; recall that NC[D] is denoted
by j = 1. Similarly, RP(D)i,2 (t) = 0 since L[C] ( j = 2)
only involves antiangiogenic therapy. The remaining release
profiles should ideally be fixed from in vivo release experi-
ments. We expect that the release profiles of combretastatin
and doxorubicin in L[CD] are similar to the release profile
of combretastatin in L[C] that is, RP(C)i,3 (t) = RP(D)i,3 (t) =
RP(C)i,2 (t)—this is due to the fact that for all these cases, drugs
are included inside a liposome. Similarly, since all nanocells
(independently of whether they contain combretastatin or
not) have liposome on the outer layer, we have RP(D)i,1 (t) =
RP(D)i,4 (t). Thus, we need to determine the functions RP
(D)
i,1 (t),
RP(C)i,2 (t), and RP
(C)
i,4 (t). The in vitro studies by Sengupta et al.
[19] show that the release of doxorubicin from NC[D] is
delayed relative to the release of combretastatin from the
liposome, with an extending time of approximately 4 days
for the liposome and an extending time of approximately 15
days for the core of the nanocell. On that basis we take
RP(D)i,1 (t) =
1
N1
θ(t − ti)(t − ti)pNC exp
(
− (t − ti)
τNC
)
,
RP(C)i,2 (t) =
1
N2
θ(t − ti)(t − ti)pL exp
(
− (t − ti)
τL
)
,
RP(C)i,4 (t) =
1
N4
θ(t − ti)(t − ti)p
′
L exp
(
− (t − ti)
τ′L
)
,
(10)
where ti = 8, 10, 12, 14, 16 days are the administration times
used in the experiments by Sengupta et al. [19], the constants
N1,2,4 are determined from the normalization condition, see
(7), and θ(x) is the unit step function (defined by θ(x) = 1
for x ≥ 1 and θ(x) = 0 otherwise). Assuming that the release
profile of L[C] and the liposome coating of the nanocell are
similar, we can set pL = p′L and τL = τ′L, in which case
(7) implies N2 = N4. Based on Sengupta et al. [19] we take
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Table 1: Numerical values for the parameters in (1) and (9) used in our simulations. In addition to the values shown, we use in the
dimensionful equations D1 = 0.32mm2/day for lung cancer and D1 = 0.46mm2/day for melanoma, ρ = 0.35 day−1 for both melanoma
and lung cancer (see Section 3.1), and a threshold for the detectability of tumor cells cth = 0.09 [22]. As explained in the main text we have
˜D3 = ˜D4 and ˜λ(C) = 100˜λ(D). The eﬀectiveness of chemotherapy and antiangiogenic therapy are parameterized by ˜A(D) = 1.65 and ˜A(C) = 0.1
for lung cancer, and by ˜A(D) = 3 and ˜A(C) = 0.3 for melanoma (see Section 3.1).
α˜1 ˜D2 α˜ ˜β γ˜ α˜2 ˜δ mlim ˜D3 ˜λ(C) ν˜(C) ν˜(D) μ˜
1.1 0.005 –1 3 –2 0.9 0.8
√
2 0.02 1300 3 0.1 8
pNC = 0.3 and τNC = 15 days, and pL = 0.1 and τL = 2 days.
For our modified nanocell therapy (see Section 3) we use the
same treatment schedules as for NC[CD] but take pNC = 0.8
in (10) with an appropriate normalization factor determined
from (7). This ensures that for all combined therapies the
nanocells and liposomes release the same total amount of
combretastatin and doxorubicin.
The function Γi(t) in (4) describes the (average) concen-
tration of the liposomes and nanocells in the blood vessels. In
using the same function Γi(t) for liposomes and nanocells we
assume that, once a therapy has been administered, changes
to the drug concentration in the blood vessels only result
from some natural decay (e.g., adsorption) independent of
the chemical composition of the particles. Thus, we set
Γi(t) = θ(t − ti) exp
(
− (t − ti)
τD
)
, (11)
where, as above, ti are again the administration times.
There is some indication (Sengupta et al. [19], see also
Figure 1) that Γi(t) is diﬀerent for liposomes and nanocells,
with an increased delivery of nanocells into the tissue
surrounding the tumor through a mechanism other than
vascular normalization. This would further increase the
eﬀect of NC[CD] relative to L[CD] through an increase in
the amount of drugs delivered to the tumor. However, in
order to allow a direct investigation of the temporal targeting
mechanism proposed by Sengupta et al. [19], we take the
Γi(t) for conventional therapies to be the same as for the
nanocell treatment and set τD = τNC.
2.5. Parameterization. Free antiangiogenesis and chemother-
apy agents are small particles which can be assumed to have
diﬀusion characteristics similar to nutrients such as oxygen,
for which experimental data is readily available. Thus, we set
˜D3 = ˜D4 in (5) and (6) and use a value of ˜D3 similar to
the diﬀusion constant of free oxygen in Kohandel et al. [22].
As mentioned earlier, the field m(x, t) stands for the average
distribution of blood vessels (rather than the exact pattern
of vasculature); thus, the diﬀusion coeﬃcients for drugs (or
nutrients) are not of the same order as diﬀusion from a
single blood vessel. Moreover, because chemotherapy agents
released from the nanocells are transported away through
blood vessels in the same way for NC[D] and NC[CD],
and ˜D3 = ˜D4, we use the same reabsorption rate μ˜ for
all treatments. Similarly as in Kohandel et al. [22] for free
oxygen, we assume that the natural decay of c and d is
not too strong and, hence, that the decay constants ν˜(C)
and ν˜(D) take smaller numerical values than μ˜. Furthermore,
combretastatin released from the liposome decays faster than
doxorubicin released from the nanocells [19], and, thus, we
take ν˜(C) > ν˜(D). On the other hand, one may expect that
doxorubicin released from the liposome during treatment
with L[CD] decays faster than doxorubicin released from
the nanocells. This would further decrease the eﬃciency of
L[CD] relative to NC[CD], but to avoid a proliferation of
parameters we use the same value ν˜(D) for all treatments.
The amount of drugs administered can be included
in our model through the values of the coeﬃcients ˜λ(C)
and ˜λ(D). In the experiments described by Sengupta et al.
[19] approximately one hundred times more combretastatin
than doxorubicin was injected, and, hence, we take ˜λ(C) =
100 ˜λ(D). Moreover, the constants ˜A(C) and ˜A(D) determine
the eﬀectiveness of a given therapy and are therefore crucial
parameters in our model. To allow a quantitative comparison
between the eﬀects of diﬀerent combined therapies, we use
the same values ˜A(C) and ˜A(D) for single and combined
therapies. It is thereby assumed that the eﬀect of a given
therapeutic agent is not influenced by the presence or
absence of another therapeutic agent. The values of all
parameters appearing in our model are fixed by fitting
volume curves for V, L[C], and NC[D] to the corresponding
experimental results [19]. Table 1 summarizes the parameter
values used in our simulations (see the appendix for the
sensitivity analysis of parameters). The results of the com-
bined treatments are then predicted by our model without
any further assumptions.
While we consider a variety of diﬀerent interactions
in our model, with the aim of not excluding any possible
mechanism for the success of the nanocell treatment a priori,
we find that only the three parameters D1, ˜A(C), and ˜A(D)
need to be adjusted to distinguish between lung carcinoma
and melanoma. Moreover, we also find that for both
lung carcinoma and melanoma the success of the nanocell
treatment relies crucially on the temporal release profiles
used by Sengupta et al. [19] and on the possibility of reab-
sorption of chemotherapeutic drugs into the bloodstream
(see Section 3), which is parameterized through μ˜. As in
Kohandel et al. [22], we use a normalized Gaussian initial
condition for n(x, t) with variance σ = 0.35 and a random
initial condition for m(x, t) evenly distributed between zero
and one. Zero initial conditions are considered for the con-
centrations of the drugs. All simulations are performed on a
cubic grid with 50 × 50 × 50 points and no-flux boundary
conditions.
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Figure 2: Curves for the tumor volume of (a) lung cancer and (b) melanoma obtained with no treatment (V), nanocells containing
only doxorubicin (NC[D]), liposomes containing only combretastatin (L[C]), liposomes with combretastatin and doxorubicin (L[CD]),
nanocells with combretastatin and doxorubicin (NC[CD]) and nanocells with combretastatin and doxorubicin but with a delayed release of
doxorubicin (NC[CD] and pNC = 0.8). The solid curves are obtained by integrating (1)–(6) in Section 2, and the data points are taken from
the experiments by Sengupta et al. [19]. The same total amount of drugs is released by liposomes and nanocells for the combined therapeutic
strategies, which corresponds to double the amount released for NC[D] and L[C] individually.
3. Results and Discussion
3.1. Consistency of Model Results. To confirm our model,
numerical simulations are performed according to the
experimental protocol of Sengupta et al. [19] on lung cancer
andmelanoma (see Figure 2). In these experiments, 2.5×105
Lewis lung carcinoma cells or 3× 105 GFP-positive BL6/F10
melanoma cells were implanted in male C57/BL6 mice, and
treatments started when tumors reached 50mm3 in volume
(after about 8 days). The kinetics of tumor growth and blood
vessel formation, as well as the data points for the control
group (V, red), are used to estimate the related model param-
eters for the case of lung cancer (see Table 1). The experi-
mental treatment schedules, as well as pharmacokinetics and
pharmacodynamics of agents, are used in the simulations to
fit the data for single administration of antiangiogenic ther-
apy (combretastatin-encapsulated liposomes, L[C], brown)
and chemotherapy (nanocells containing doxorubicin but
lacking combretastatin, NC[D], blue). The corresponding
curves for melanoma are obtained by modifying three model
parameters describing the diﬀusion of cancer cells and the
eﬀect of therapeutic agents on the vascular network and
cancer cells (see Section 2). We then perform numerical
simulations with the estimated parameters to predict the
results for the conventional (a liposome encapsulating
both doxorubicin and combretastatin, L[CD], green) and
nanocell (NC[CD], purple) approaches for the combination
of antiangiogenic and cytotoxic treatments.
As shown in Figure 2, the numerical results (solid lines)
obtained from our phenomenological model reproduce the
major trends observed in the experiments by Sengupta et al.
[19] (points) for lung cancer and melanoma. While the
conventional combination of combretastatin and doxoru-
bicin only produces a doubling eﬀect compared to the single
administration of combretastatin or doxorubicin, nanocells
clearly show amore pronounced eﬀect with the same amount
of drugs administered. Our simulations strongly support the
hypothesis that the increased eﬀect of the nanocell treatment
is mainly due to the temporal release achieved through
nanocells [19], which is from a mathematical perspective the
only feature distinguishing L[CD] andNC[CD] in ourmodel
(see Section 2). This is discussed further in the following.
In the study by Sengupta et al. [19], the results of the
single therapies NC[D] and L[C] were also compared to
the coadministration of NC[D] and L[C] (NC[D] + L[C]).
However, NC[D] + L[C] only showed a negligible eﬀect
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Figure 3: Mechanisms for the temporal targeting of tumor cells and neovasculature. (a) Nanocells are delivered to the tumor tissue through
the neovasculature and rapidly release antiangiogenic agents. (b) The vascular collapse leads to the trapping of the chemotherapeutic agents
within the tumor tissue and thereby prevents reabsorption into the bloodstream. According to our mathematical model this is the principal
mechanism responsible for the superior results of the nanocell treatment found by Sengupta et al. [19]. (c) The normalization of tumor blood
vessels produced by the antiangiogenic therapy leads to a transient “window of opportunity” [2] during which the delivery of nanocells
into the tumor tissue is enhanced. (d) Our model suggests that through a judicious timing of the release profiles the interplay between
normalization and vascular collapse can be utilized to improve the eﬃcacy of the nanocell treatment.
when compared to either of the treatments alone. This is
probably due to a limitation on the total number of nanocells
or liposomes which can be taken up by the tumor tissue at
any given time. This limitation does not aﬀect any of the
other more eﬀective combination strategies considered in
Sengupta et al. [19] and, thus, we do not discuss this case
in our modeling approach.
3.2. Synergistic Eﬀect of Nanocell Treatment. Our model
predicts the nanocell treatment can produce a combined
eﬀect that is greater than the sum of its parts through
the two diﬀerent mechanisms illustrated in Figure 3. First,
the transient normalization resulting from antiangiogenic
therapy enhances the delivery of additional nanocells to
the tumor tissue. This in turn increases the eﬀect of the
subsequent release of chemotherapy. Second, antiangiogenic
therapy can also cut oﬀ the blood supply to the tumor,
which eﬀectively traps the cytotoxic drugs within the tumor
tissue. Thus, smaller amounts of free chemotherapy agents
are transported away from the tumor tissue. According to
our simulations, the latter mechanism is crucial for obtaining
the superior results of NC[CD] reported by Sengupta et al.
[19], while normalization only brings a small increase in
the eﬀectiveness of NC[CD] relative to L[CD]. However,
as discussed later, normalization can still be employed to
further improve the eﬃcacy of the nanocell treatment.
As mentioned earlier, our modelling hypothesis is that
by adjusting the interplay between normalization and the
temporal targeting described by Sengupta et al. [19] an
improved therapeutic outcome can be achieved. To validate
this hypothesis, we modeled diﬀerent release profiles for the
nanocell core which delay the secretion of chemotherapy
relative to antiangiogenic therapy even further than the
release profile considered in the experiments of Sengupta
et al. [19] (see Section 3). We were careful to adjust the
delayed release profiles such that over the course of the
treatment the same total amount of antiangiogenic and
chemotherapeutic agents was released as in the combination
therapies, L[CD] and NC[CD], considered before. Thus,
compared to the conventional nanocell therapy, with our
modified release profiles more chemotherapeutic agents
are released by nanocells administered at early times, but
correspondingly fewer chemotherapeutic drugs are released
by nanocells administered at later times.
The simulation results indicate that with the adjusted
release kinetics a substantial improvement in the eﬃcacy of
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Figure 4: Sensitivity analysis for L[CD] and NC[CD] in Lewis
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the nanocell treatment can be achieved (see the black curves
in Figure 2). As illustrated in Figure 3, this improved result
is due to a combination of normalization, which is mainly
eﬀective in the early stages of the therapy and increases the
fraction of nanocells delivered to the tumor tissue at early
times, and the vascular shutdown induced by antiangiogenic
therapy, which decreases the fraction of nanocells delivered at
later times and traps the chemotherapeutic agents within the
tumor tissue. Our modified release profiles take advantage
of these two eﬀects and lead to better coordination between
the arrival of nanocells in the tumor tissue and the release
of antiangiogenic and chemotherapeutic agents. Thus, our
simulations suggest that, by means of a judicious timing of
normalization and the trapping of chemotherapeutic agents
in the tumor tissue through the release of combretastatin, a
better therapeutic outcome can be achieved.
In summary, mathematical models can be used to
simulate various therapeutic scenarios and aid in hypothesis
testing “in silico” and conversely to guide experimental
research. Following the very successful experimental results
of Sengupta et al. [19] and experimental and clinical studies
on the normalization process of tumor vasculature [10–
12], we have developed a mathematical formulation that
captures the qualitative picture proposed by Sengupta and
coworkers. On the basis of this model we find that the
dramatically improved therapeutic eﬀect of the nanocell
treatment demonstrated by Sengupta et al. [19] primarily
results from the trapping of chemotherapeutic agents, rather
than an increase in the number of nanocells delivered to
the tumor through normalization. Moreover, we find that
through an adjustment of the release kinetics for chemother-
apy it may be possible to substantially improve the eﬃcacy
of the nanocell treatment. As a result of our promising
computational results, it seems clear that more experimental
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Figure 5: The tumor volume obtained with a 5% increase in (a) α˜1
and (b) ˜δ for Lewis lung carcinoma.
and preclinical data are required to further validate this
strategy for improved therapeutic outcome. In particular,
our model results suggest that nanocells with a longer delay
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in the secretion of chemotherapy relative to antiangiogenic
therapy (compared to the release profile considered in the
experiments of Sengupta et al. [19]) may further increase
the eﬃciency of the treatment. Our computational approach
could be also used to design nanocells for other types of
cancers, and to quantitatively determine promising release
profiles.
Appendix
In this appendix we investigate the eﬀect of variations in the
values of the model parameters on our model predictions. To
study parameter sensitivity, we calculate the eﬀect of small
changes of the parameters on final tumor volume (at day
17). We determine the percent change in the final tumor
volume when the model parameters are perturbed from
their estimated values by 5% [25]. Figure 4 shows the results
for the case of combination therapies using nanocells and
liposomes, that is, NC[CD], and L[CD], in lung cancer. One
should note that changing ˜λ(C) = 100˜λ(D) has the same eﬀect
as varying ˜δ; in addition, the parameters α˜, ˜β, and γ˜ are
not changed as they are responsible for the creation of the
vascular network (see main text). The results indicate that
the parameters α˜1 and ˜δ contribute most significantly to the
final tumor volume; however, these contributions are smaller
in L[CD] compared to NC[CD].
To investigate whether the trends obtained from our
model for diﬀerent treatments are robust with respect to
changes in the model parameters, we performed numerical
simulations of our model using parameterizations for which
α˜1 or ˜δ were increased by 5% while all other model
parameters were held fixed. As shown in Figure 5, these
variations do not aﬀect the trends illustrated in Figure 2(a).
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